The Menopausal Musculoskeletal Shift: Exploring Questions Around PRP, Strength, and Tissue Health
-2.png?width=1600&height=900&name=Naturopathic%20February%20Webinar%20(1)-2.png)
Educational webinar highlight presented by Brittany Krake, ND, MDR (February 2026)
Hormones, Tissue Biology, and Emerging Questions Around PRP
During a recent educational webinar hosted by APEX Biologix, Brittany Krake, ND, MDR, explored an emerging conversation in musculoskeletal medicine: how hormonal changes during the menopausal transition may influence tissue biology and regenerative therapy response.
In the educational webinar session, Dr. Krake examines the intersection of women’s health, musculoskeletal physiology, and orthobiologic therapies, with a focus on how endocrine changes may shape the biologic environment in which tissue repair occurs.
The discussion raises an important clinical question for regenerative practitioners:
Could endocrine context influence regenerative outcomes?
Joint Pain in Midlife Women: A Common Clinical Pattern
Joint pain, stiffness, and reduced tissue resilience are frequently reported during the menopausal transition. Research suggests that up to 70% of menopausal women experience joint pain, making it one of the most common symptoms after vasomotor changes such as hot flashes.
At the same time, many patients present with musculoskeletal symptoms without clear structural abnormalities on imaging. Estimates suggest that approximately 40% of midlife women experiencing musculoskeletal pain may show no visible structural findings, which can delay diagnosis or treatment.
This constellation of symptoms has recently been described as the musculoskeletal syndrome of menopause, which may include:
- Joint pain
- Tendinopathy
- Stiffness
- Muscle loss
- Accelerated tissue degeneration
These observations suggest that systemic biologic changes not just localized orthopedic injury may contribute to musculoskeletal symptoms during this stage of life.
The Menopausal Musculoskeletal Shift Explained
In the segment below, Dr. Krake explains why joint pain is one of the most common symptoms reported during the menopausal transition and how it may reflect broader physiologic changes rather than isolated orthopedic injury.
The Musculoskeletal System Is Hormone Responsive
A key concept discussed during the webinar is that musculoskeletal tissues are endocrine responsive.
Bone, skeletal muscle, tendons, ligaments, and cartilage contain receptors for major sex hormones including estrogen, progesterone, and testosterone.
These hormones regulate several processes essential for tissue maintenance and repair, including:
- collagen synthesis
- matrix turnover
- cellular signaling
- tissue remodeling
Because regenerative therapies such as platelet-rich plasma (PRP) rely on these same biologic pathways, hormonal signaling may influence how tissues respond to treatment.
Hormonal Changes and Tissue Biology
During perimenopause and menopause, hormone levels do not decline uniformly.
Progesterone often declines earlier, while estrogen levels may fluctuate significantly during the perimenopausal transition before ultimately decreasing.
These hormonal shifts may influence musculoskeletal tissues in several ways, including:
- increased bone resorption
- altered tendon stiffness
- reduced muscle repair capacity
- changes in cartilage metabolism
Postmenopausal women also demonstrate increased prevalence of conditions such as osteoarthritis and sarcopenia, highlighting the systemic influence of endocrine signaling on musculoskeletal health.
Implications for Regenerative Therapies
Orthobiologic treatments such as PRP stimulate biologic repair processes, including:
- growth factor signaling
- cellular proliferation
- collagen production
- matrix remodeling
PRP contains platelets that release growth factors such as PDGF, TGF-β, and IGF-1 that contribute to tissue repair and regeneration.
However, these biologic pathways function within a broader physiologic environment.
Two patients may present with the same diagnosis and receive the same regenerative injection, yet their endocrine environments may differ significantly.
As discussed in the webinar:
Two patients can receive the same injection but respond differently because their endocrine environments are different.
Understanding this broader biologic context may help explain variability in regenerative outcomes observed in clinical practice.
Watch the On-Demand Webinar
To explore the full discussion, including detailed physiologic insights, clinical observations, and case examples, watch the on-demand webinar recording featuring Brittany Krake, ND, MDR.
You can also explore additional clinician education resources, research summaries, and webinar recordings in the APEX Resource Library.
References
Gilmer, G., et al. Female aging: when transitional models don’t translate. Nat Aging. 2024;4:20-29. doi: 10.1038/s43587-023-00509-8
Segal, N., et al. Sex differences in osteoarthritis prevalence, pain perception, physical function and therapeutics. Osteoarthritis Cartilage. 2024;32(9):1045-1053. doi: 10.1016/j.joca.2024.04.002
Katz, J., et al. Diagnosis and Treatment of Hip and Knee Osteoarthritis: A Review. JAMA. 2021;325(6):568-578. doi: 10.1001/jama.2020.22171
Faber, B., et al. Sex Differences in the radiographic and symptomatic prevalence of knee and hip osteoarthritis. Front Endocrinol (Lausanne). 2024;15:1445468. doi: 10.3389/fendo.2024.1445468
Petermann-Rocha, F., et al. Global prevalence of sarcopenia and severe sarcopenia: a systematic review and meta-analysis. J Cachexia Sarcopenia Muscle. 2022;13(1):86-99. doi: 10.1002/jcsm.12783
Hwang, J & Park, S. Gender-Specific Risk Factors and Prevalence for Sarcopenia among Community-Dwelling Young-Old Adults. Int J Environ Res Public Health. 2022;19(12):7232. doi: 10.3390/ijerph19127232
Yang, L., et al. Gender-specific risk factors for incident sarcopenia: 8-year follow-up of the English longitudinal study of ageing. J Epidemiol Community Health. 2019;73(1):86-88. doi: 10.1136/jech-2018-211258
Park, YM., et al. Appendicular lean mass is lower in late compared with early perimenopausal women: potential role of FSH. J Appl Physiol. 2020;128(5):1373-1380. doi: 10.1152/japplphysiol.00315.2019
Nappi, R., et al. Menopause: a cardiometabolic transition. Lancet Diabetes Endocrinol. 2022;10(6):442-456. doi: 10.1016/S2213-8587(22)00076-6
Parenteau, C., et al. Prevalence of spine degeneration diagnosis by type, age, gender, and obesity using Medicare data. Sci Rep. 2021;11(1):5389. doi: 10.1038/s41598-021-84724-6
Lou, C., et al. Association between menopause and lumbar disc degeneration: an MRI study of 1,566 women and 1,382 men. Menopause. 2017;24(10):1136-1144. doi: 10.1097/GME.0000000000000902
Wang, Y-X., et al. Relationship between gender, bone mineral density, and disc degeneration in the lumbar spine: a study in elderly subjects using an eight-level MRI-based disc degenerative grading system. Osteoporos Int. 2011;22(1):91-96. doi: 10.1007/s00198-010-1200-y
Gold, E., et al. The Longitudinal Relation of Inflammation to Incidence of Vasomotor Symptoms. Menopause. 2022;29(8):894-904. doi: 10.1097/GME.0000000000002005
Wright, V., et al. The musculoskeletal syndrome of menopause. Climacteric. 2024;27(5):466-472. doi: 10.1080/13697137.2024.2380363
Lu CB, Liu PF, Zhou YS, et al. Musculoskeletal pain during the menopausal transition: a systematic review and meta-analysis. Neural Plast. 2020;2020:8842110–8842110. doi: 10.1155/2020/8842110.
Xiong G, Lingampalli N, Koltsov JCB, Leung LL, Bhutani N, Robinson WH, Chu CR. Men and Women Differ in the Biochemical Composition of Platelet-Rich Plasma. Am J Sports Med. 2018 Feb;46(2):409-419. doi: 10.1177/0363546517740845. Epub 2017 Dec 6. PMID: 29211968; PMCID: PMC8487642.
Wright VJ, Schwartzman JD, Itinoche R, Wittstein J. The musculoskeletal syndrome of menopause. Climacteric. 2024 Oct;27(5):466-472. doi: 10.1080/13697137.2024.2380363. Epub 2024 Jul 30. PMID: 39077777.